[go: up one dir, main page]

PE20180454A1 - Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2 - Google Patents

Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2

Info

Publication number
PE20180454A1
PE20180454A1 PE2017002462A PE2017002462A PE20180454A1 PE 20180454 A1 PE20180454 A1 PE 20180454A1 PE 2017002462 A PE2017002462 A PE 2017002462A PE 2017002462 A PE2017002462 A PE 2017002462A PE 20180454 A1 PE20180454 A1 PE 20180454A1
Authority
PE
Peru
Prior art keywords
antibody
inhibitor
bcl
combined therapy
mdm2
Prior art date
Application number
PE2017002462A
Other languages
English (en)
Inventor
Christian Klein
Frank Herting
Markus Dangl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20180454A1 publication Critical patent/PE20180454A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a un anticuerpo anti-CD20 en combinacion con un inhibidor de Bcl-2 y un inhibidor de MDM2 para el tratamiento del cancer. Dicho anticuerpo es un anticuerpo anti-CD20 de tipo I no fucosilado, o un anticuerpo B-Ly1 humanizado. Este anticuerpo es utilizado especialmente a la terapia combinada de canceres que expresan CD20, como linfoma o leucemia linfocitica.
PE2017002462A 2015-05-26 2016-05-23 Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2 PE20180454A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15169199 2015-05-26

Publications (1)

Publication Number Publication Date
PE20180454A1 true PE20180454A1 (es) 2018-03-05

Family

ID=53264535

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002462A PE20180454A1 (es) 2015-05-26 2016-05-23 Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2

Country Status (30)

Country Link
US (1) US20160347852A1 (es)
EP (1) EP3302549B1 (es)
JP (1) JP6612362B2 (es)
KR (1) KR102043803B1 (es)
CN (1) CN107847600B (es)
AR (1) AR104735A1 (es)
AU (1) AU2016267564B2 (es)
BR (1) BR112017023517A2 (es)
CA (1) CA2984706A1 (es)
CL (1) CL2017002983A1 (es)
CR (1) CR20170529A (es)
DK (1) DK3302549T3 (es)
ES (1) ES2744624T3 (es)
HR (1) HRP20191585T1 (es)
HU (1) HUE044853T2 (es)
IL (1) IL255353B (es)
LT (1) LT3302549T (es)
MA (1) MA44645B1 (es)
MX (1) MX389342B (es)
MY (1) MY188849A (es)
NZ (1) NZ736727A (es)
PE (1) PE20180454A1 (es)
PL (1) PL3302549T3 (es)
PT (1) PT3302549T (es)
RS (1) RS59204B1 (es)
RU (1) RU2727196C2 (es)
SI (1) SI3302549T1 (es)
UA (1) UA124617C2 (es)
WO (1) WO2016188935A1 (es)
ZA (1) ZA201707357B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002947A (es) 2012-09-07 2015-09-23 Genentech Inc Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
SG10202104036QA (en) 2016-10-28 2021-05-28 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20210106703A1 (en) * 2017-11-22 2021-04-15 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
AU2019207616A1 (en) 2018-01-10 2020-07-09 Recurium Ip Holdings, Llc Benzamide compounds
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
AU2019315466B2 (en) * 2018-07-31 2022-05-19 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
TWI725488B (zh) 2018-07-31 2021-04-21 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
RU2013131444A (ru) * 2010-12-16 2015-01-27 Рош Гликарт Аг Сочетанная терапия афукозилированным антителом к cd20 и ингибитором mdm2

Also Published As

Publication number Publication date
PT3302549T (pt) 2019-09-09
DK3302549T3 (da) 2019-09-16
CN107847600A (zh) 2018-03-27
NZ736727A (en) 2022-09-30
MX389342B (es) 2025-03-20
IL255353A0 (en) 2017-12-31
AU2016267564B2 (en) 2022-09-01
RS59204B1 (sr) 2019-10-31
AU2016267564A1 (en) 2017-11-16
MY188849A (en) 2022-01-09
AR104735A1 (es) 2017-08-09
CR20170529A (es) 2018-01-26
MA44645B1 (fr) 2019-09-30
JP2018515583A (ja) 2018-06-14
ZA201707357B (en) 2020-05-27
IL255353B (en) 2021-08-31
HRP20191585T1 (hr) 2019-11-29
JP6612362B2 (ja) 2019-11-27
CL2017002983A1 (es) 2018-05-04
EP3302549B1 (en) 2019-07-03
BR112017023517A2 (pt) 2018-07-24
RU2727196C2 (ru) 2020-07-21
CA2984706A1 (en) 2016-12-01
RU2017145649A3 (es) 2019-10-23
UA124617C2 (uk) 2021-10-20
EP3302549A1 (en) 2018-04-11
ES2744624T3 (es) 2020-02-25
RU2017145649A (ru) 2019-06-26
KR20180004285A (ko) 2018-01-10
CN107847600B (zh) 2021-09-03
KR102043803B1 (ko) 2019-11-12
HK1252855A1 (zh) 2019-06-06
US20160347852A1 (en) 2016-12-01
MX2017014977A (es) 2018-03-23
HUE044853T2 (hu) 2019-11-28
PL3302549T3 (pl) 2019-11-29
LT3302549T (lt) 2019-09-25
SI3302549T1 (sl) 2019-10-30
WO2016188935A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
PE20180454A1 (es) Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2
MX2016005801A (es) Terapia de combinacion de un anticuerpo anti cd20 con un inhibidor de btk.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2016013863A (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2017005553A (es) Terapia de combinacion para cancer.
MX2017013178A (es) Terapia de combinacion para cancer.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
DOP2016000225A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112017011749A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia mieloide aguda
MX2020003770A (es) Terapias de combinacion para tratar cancer.
CL2019000658A1 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo.
EA201991818A1 (ru) Лечение рака
DOP2019000019A (es) Metodos para tratar el cancer de prostata
MX2019009304A (es) Tratamiento para el cancer.
MX370829B (es) Uso de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd22-fármaco.
BR112019003130A2 (pt) agonista de ppargama para tratamento de cânceres de sangue
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.